Medical Condition News

RSS

Generic drugs to treat hypertension, heart failure could help NHS save £200 million

Using a generic drug to treat hypertension and heart failure, instead of branded medicines from the same class, could save the UK National Health Service (NHS) at least £200 million in 2011 without any real reduction in clinical benefits.

3 Feb 2011

UT Southwestern leads national effort to find effective treatments for drug addiction

UT Southwestern Medical Center psychiatry researchers are leading the Texas arm of a national network that conducts clinical trials aimed at finding effective treatments for drug addiction.

3 Feb 2011

Ta`am Teva Altman, Probi sign agreement to launch dietary supplement for gut health

Probi has signed an agreement giving Ta`am Teva Altman rights to launch Probi's dietary supplement for gut health based on Lp299v™ in Israel. The launch is planned to take place in the second quarter of 2011.

3 Feb 2011

Lead exposure can lead to high blood pressure in pregnant women: Study

Even minute amounts of lead may take a toll on pregnant women, according to a study published by Lynn Goldman, M.D., M.S., M.P.H., Dean of George Washington University's School of Public Health and Health Services in D.C., and colleagues, in the journal Environmental Health Perspectives.

3 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

Study reveals how MMSET gene enables disease-causing mutations to occur

For several decades, researchers have been linking genetic mutations to diseases ranging from cancer to developmental abnormalities. What hasn't been clear, however, is how the body's genome sustains such destructive glitches in the first place.

3 Feb 2011

Metamark announces Nature journal published landmark prostate cancer study results

Metamark Genetics, Inc., a privately-held oncology molecular diagnostics company, today announced results from a landmark prostate cancer study published as an Advance Online Publication in the journal Nature.

3 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

Inspiration presents IB1001 PK data at European haemophilia congress

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. (Inspiration) presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Researchers to develop new diagnostics platform for early detection of lung cancer

The earlier cancers can be detected, the better the chances of a cure. Researchers are now working to develop a new diagnostics platform with which the illness can be diagnosed in its early stages, even during a visit to the general practitioner: protein biomarkers in exhaled air divulge the presence of pathological cells in the lung.

3 Feb 2011

Cervical cancer screening rates are quite low among older, poorer South Asians

Immigrant women in Ontario are not screened for cervical cancer as often as native-born Canadians, with the lowest rates being among older, poorer South Asians, new research shows.

3 Feb 2011

HealthCore, AstraZeneca collaborate to conduct real-world studies on disease states, treatment

AstraZeneca Pharmaceuticals LP and HealthCore, the health outcomes research subsidiary of WellPoint, today announced a collaborative agreement to conduct real-world studies designed to determine how to most effectively and economically treat disease.

3 Feb 2011

Prehabilitation before knee replacement surgery may improve functional ability in osteoarthritis patients

An exercise program designed by researchers at the University of Louisville for patients with severe knee arthritis improves leg strength and patients' functional ability before knee replacement surgery, according to recent report in The Journal of Strength and Conditioning Research.

3 Feb 2011

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

Isotechnika Pharma Inc. is pleased to announce that it has finalized the Development, Distribution and License Agreement with ILJIN Life Science Co., Ltd., previously announced on November 16, 2010. Isotechnika will now receive the license fee of US$4.5 million plus proceeds of US$2.375 million from ILJIN's purchase of its first tranche of Common Shares from treasury.

3 Feb 2011

FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate

Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.

3 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

FDA disallows obesity drug Contrave pending further large-scale testing

In its latest blow to obesity medication development efforts, the US Food and Drug Administration (FDA) yesterday notified Orexigen Therapeutics that it would need to conduct an extremely large-scale study of the long-term cardiovascular effects of its drug, Contrave, before approval could be considered.

3 Feb 2011

New research: Homophobic social environments may disrupt hormonal responses in LGB adults

Young adults who are lesbian, gay or bisexual are at far higher risk for severe mental health problems than their heterosexual peers. New research from Concordia University suggests that the stress of being rejected or victimized because of sexual orientation may disrupt hormonal responses in lesbians, gays and bisexuals.

3 Feb 2011

International scientist team identifies gene mutation strongly linked to schizophrenia

In a major advance for schizophrenia research, an international team of scientists, led by Jonathan Sebat, PhD, assistant professor of psychiatry and cellular and molecular medicine at the University of California, San Diego School of Medicine, has identified a gene mutation strongly linked to the brain disorder - and a signaling pathway that may be treatable with existing compounds.

3 Feb 2011

Medical Condition News

Generic drugs to treat hypertension, heart failure could help NHS save £200 million

UT Southwestern leads national effort to find effective treatments for drug addiction

Ta`am Teva Altman, Probi sign agreement to launch dietary supplement for gut health

Lead exposure can lead to high blood pressure in pregnant women: Study

Losartan improves effectiveness of nanotherapeutics against cancer

Study reveals how MMSET gene enables disease-causing mutations to occur

Metamark announces Nature journal published landmark prostate cancer study results

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Inspiration presents IB1001 PK data at European haemophilia congress

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Researchers to develop new diagnostics platform for early detection of lung cancer

Cervical cancer screening rates are quite low among older, poorer South Asians

HealthCore, AstraZeneca collaborate to conduct real-world studies on disease states, treatment

Prehabilitation before knee replacement surgery may improve functional ability in osteoarthritis patients

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

FDA disallows obesity drug Contrave pending further large-scale testing

New research: Homophobic social environments may disrupt hormonal responses in LGB adults

International scientist team identifies gene mutation strongly linked to schizophrenia

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News